文献速递产科母胎医学

促甲状腺激素、抗甲状腺抗体与妊娠结局

Thyroid-stimulating hormone, anti-thyroid antibodies, and pregnancy outcomes.
PubMed 文献 · Am J Obstet Gynecol · 2017-09-14

本研究为一项多中心随机安慰剂对照试验的二次分析,纳入1193例有1-2次既往妊娠丢失的18-40岁女性,检测孕前促甲状腺激素、游离甲状腺素、甲状腺球蛋白抗体和甲状腺过氧化物酶抗体。结果显示,孕前促甲状腺激素>2.5 vs ≤2.5 mIU/L及甲状腺抗体阳性与早产、妊娠期糖尿病和子痫前期均无关联。

要点

  • 孕前促甲状腺激素>2.5 vs ≤2.5 mIU/L与早产、妊娠期糖尿病、子痫前期无关联。
  • 甲状腺抗体阳性 vs 阴性女性早产、妊娠期糖尿病、子痫前期风险未增加。
  • 数据支持当前推荐:低危无症状女性不应常规筛查甲状腺功能或自身免疫。

核心结论

  • 在有1-2次既往妊娠丢失的女性中,亚临床甲状腺功能减退和甲状腺自身免疫与早产、妊娠期糖尿病或子痫前期风险增加无关。
  • 这些数据支持当前推荐,即低危无症状女性不应常规筛查甲状腺功能障碍或自身免疫。

研究设计与样本

  • 研究为一项多中心随机安慰剂对照低剂量阿司匹林试验的二次分析,纳入18-40岁、有1-2次既往妊娠丢失的女性(n=1193)。
  • 检测孕前促甲状腺激素、游离甲状腺素、甲状腺球蛋白抗体和甲状腺过氧化物酶抗体水平。
  • 采用广义线性模型估计相对风险及95%置信区间,并校正年龄和体重指数。

主要发现

  • 在估计孕龄>20周的持续妊娠女性中,孕前促甲状腺激素>2.5 vs ≤2.5 mIU/L与早产无关联(校正相对风险0.77;95%置信区间0.40-1.47)。
  • 孕前促甲状腺激素>2.5 vs ≤2.5 mIU/L与妊娠期糖尿病无关联(校正相对风险1.28;95%置信区间0.54-3.04)。
  • 孕前促甲状腺激素>2.5 vs ≤2.5 mIU/L与子痫前期无关联(校正相对风险1.20;95%置信区间0.71-2.04)。
  • 甲状腺抗体阳性 vs 阴性女性早产风险未增加(相对风险1.26;95%置信区间0.65-2.45)。
  • 甲状腺抗体阳性 vs 阴性女性妊娠期糖尿病风险未增加(相对风险1.33;95%置信区间0.51-3.49);子痫前期风险未增加(相对风险1.02;95%置信区间0.54-1.92)。

临床怎么用

  • 作者结论指出,这些数据支持当前推荐,即低危无症状女性不应常规筛查甲状腺功能障碍或自身免疫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overt thyroid dysfunction has been associated with adverse obstetric outcomes. However, less is known regarding subclinical hypothyroidism or thyroid autoimmunity and their relationship to pregnancy complications. OBJECTIVE: The purpose of this study was to examine the association between prepregnancy anti-thyroid antibodies and subclinical hypothyroidism and preterm delivery, gestational diabetes mellitus, and preeclampsia. STUDY DESIGN: We conducted a secondary analysis of a prospective cohort of 18- to 40-year-old women with 1-2 previous pregnancy losses (n=1193) who participated in a multicenter randomized, placebo-controlled trial of low-dose aspirin. Prepregnancy levels of thyroid-stimulating hormone, free thyroxine, thyroglobulin antibody, and thyroid peroxidase antibody were measured. Relative risks and 95% confidence intervals were estimated with the use of generalized linear models with adjustment for age and body mass index. RESULTS: Among women with an ongoing pregnancy of >20 weeks estimated gestational age, there was no association between prepregnancy thyroid-stimulating hormone level (>2.5 vs ≤2.5 mIU/L) and preterm delivery (adjusted relative risk, 0.77; 95% confidence interval, 0.40-1.47), gestational diabetes mellitus (adjusted relative risk, 1.28; 95% confidence interval, 0.54-3.04), or preeclampsia (adjusted relative risk, 1.20; 95% confidence interval, 0.71-2.04). Similarly, among women with thyroid antibodies, there was no increase in the likelihood of preterm delivery (relative risk, 1.26; 95% confidence interval, 0.65-2.45), gestational diabetes mellitus (relative risk, 1.33; 95% confidence interval, 0.51-3.49), or preeclampsia (relative risk, 1.02; 95% confidence interval, 0.54-1.92), compared with women without these antibodies. CONCLUSION: Among women with 1-2 previous pregnancy losses, subclinical hypothyroidism and thyroid autoimmunity were not associated with an increased risk of preterm delivery, gestational diabetes mellitus, or preeclampsia. These data support current recommendations that low-risk asymptomatic women should not be screened routinely for thyroid dysfunction or autoimmunity.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Plowden TC, Schisterman EF, Sjaarda LA, et al. Thyroid-stimulating hormone, anti-thyroid antibodies, and pregnancy outcomes. Am J Obstet Gynecol. 2017. PMID: 28917612. doi:10.1016/j.ajog.2017.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。